Weekly Digest – January 2026 Weekly Digest – January 2026 30 December 2025: CellBion seeks conditional approval for prostate cancer treatment candidate 177Lu-pocuvotide CellBion completed submission of a conditional approval application on December 30 to the Ministry of Food and […]
Weekly Digest – January 2026 Weekly Digest – January 2026 29 December 2025: Alphamab Oncology announces IND application for a Phase 3 clinical study of HER2 bispecific ADC subcutaneous co-formulation JSKN033 as first-line treatment of advanced cervical cancer was officially […]
Weekly Digest – January 2026 Weekly Digest – January 2026 26 December 2025: Junshi Biosciences EGFR-HER3 bispecific antibody ADC has successfully advanced to its global Phase 2 clinical trial, ranking second in the world Junshi Biosciences has recently registered a […]
Weekly Digest – January 2026 Weekly Digest – January 2026 28 December 2025: Senhwa Biosciences aims at a multi-billion dollar global market with CX-5461 combined with ADC “blockbuster” therapy Senhwa Biosciences announced a Phase 1 clinical trial evaluating its first-in-class […]
Weekly Digest – January 2026 Weekly Digest – January 2026 29 December 2025: Harbour BioMed enters into long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates Harbour BioMed entered a long-term strategic collaboration with Yantai Lannacheng Biotechnology to […]
Weekly Digest – January 2026 Weekly Digest – January 2026 31 December 2025: BioAtla and GATC health announce a $40 million special purpose vehicle (SPV) transaction to advance Ozuriftamab Vedotin (Oz-V) into a registrational trial for 2L+ oropharyngeal squamous cell […]
